Developing Safe & Effective, Non-Opioid Based Pain Therapeutics
Zymedyne aims to develop safer, more effective treatments for chronic, neuropathic pain by targeting human Cav3.2 “T-type” calcium channels that are known to be crucial in pain signalling. Unlike opioids, our technology aims to achieve pain relief without the detrimental side effects of weight gain, respiratory depression and addiction that plague current users of opioid-based medications.
Chronic pain is a debilitating condition that affects up to 30% of adult Canadians and is one of the most serious health challenges that faces society today. Current therapies are not universally effective and often have detrimental adverse effects, such as weight gain (e.g., Gabapentinoids), respiratory depression (opioids) and addiction (opioid crisis). As a result, many patients are left with unmanaged chronic pain and new approaches are sorely needed.
Zymedyne holds the IP on a newly discovered molecular mechanism that causes increased T-Type calcium channel expression and elevated pain signals. This non-opioid dependent mechanism provides an exciting avenue for finding drugs that can regulate pain without the detrimental side effects of opioids. We are currently developing and refining small organic compounds that target this mechanism. Our aim is to continue developing these and other ion channel targeting compounds, with the ultimate goal of providing safer, non opioid-based pain-relieving alternatives to chronic pain sufferers.
In short, our mission is to develop next generation Non-opioid based Analgesics to improve Patient Quality of life.